Do spermicides containing nonoxynol-9 prevent sexually transmitted infections?: A meta-analysis

Sexually Transmitted Diseases

Volumn 25, Issue 3, 1998, Pages 144-150

  Cook, Robert L ^a,c   Rosenberg, Michael J ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Health Decisions Inc   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONOXINOL 9; SPERMICIDAL AGENT;

ARTICLE; CHLAMYDIASIS; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; GONORRHEA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTRAVAGINAL DRUG ADMINISTRATION; META ANALYSIS; SEXUALLY TRANSMITTED DISEASE;

CHLAMYDIA--PREVENTION AND CONTROL; CONTRACEPTION; CONTRACEPTIVE AGENTS; DISEASES; FAMILY PLANNING; GONORRHEA--PREVENTION AND CONTROL; HIV INFECTIONS--PREVENTION AND CONTROL; INFECTIONS; LITERATURE REVIEW; NONOXYNOL-9; REPRODUCTIVE TRACT INFECTIONS; SEXUALLY TRANSMITTED DISEASES; SPERMICIDAL CONTRACEPTIVE AGENTS; VIRAL DISEASES;

CHLAMYDIA INFECTIONS; FEMALE; GONORRHEA; HIV INFECTIONS; HUMANS; MALE; NONOXYNOL; SEXUALLY TRANSMITTED DISEASES; SPERMATOCIDAL AGENTS;

EID: 0031905984     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007435-199803000-00007     Document Type: Article

References (60)

1. Institute of Medicine. The Hidden Epidemic: Confronting Sexually Transmitted Diseases. Washington, DC: National Academy Press, 1997.
2. Rosenberg M, Gollub EL. Commentary: Methods women can use that may prevent sexually transmitted disease, including HIV. Am J Public Health 1992; 82:1473-1478.
3. Centers for Disease Control and Prevention. Update: AIDS among women-United States, 1994. MMWR Morb Mortal Wkly Rep 1995; 44:81-84.
4. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd ed. Baltimore: Williams & Wilkins, 1996.
5. Centers for Disease Control and Prevention. Update: Barrier protection against HIV infection and other sexually transmitted diseases. MMWR Morb Mortal Wkly Rep 1993;42:589-591.
6. Cates W, Stone K. Family planning, sexually transmitted diseases and contraceptive choice: A literature update - part I. Fam Plann Perspect 1992;24:75-84.
7. Feldblum PJ, Morrison CS, Roddy RE, Cates WJ. The effectiveness of barrier methods of contraception in preventing the spread of HIV. AIDS 1995; 9(Suppl A):S85-S93.
8. Weeks MR, Schensul JJ, Williams SS, Singer M, Grier M. AIDS prevention for African-American and Latina women: Building culturally and gender-appropriate intervention. AIDS Educ Prevent 1995; 7:251-263.
9. Stein Z. HIV prevention: The need for methods women can use. Am J Public Health 1990; 80:460-461.
10. Elias C. Heise L. Challenges for the development of female-controlled vaginal microbicides. AIDS 1994; 8:1-9.
11. Hicks D, Martin L, Getchell J, et al. Inactivation of HTLV-III/LAV-infected cultures of normal human lymphocytes by nonoxynol-9 in vitro (letter). Lancet 1985; 2:1422-1423.
12. Judson FN, Ehret JM, Bodin G, Levin M, Rietmeijer C. In vitro evaluations of condoms with and without nonoxynol-9 as physical and chemical barriers against Chlamydia trachomatis, herpes simplex virus type 2, and human immunodeficiency virus. Sex Transm Dis 1989; 16:51-56.
13. Singh B, Cutler JC, Utidjian HMD. Studies of the development of a vaginal preparation providing both prophylaxis against venereal disease and other genital infections and contraception: II. Effect in vitro of vaginal contraceptive and non-contraceptive preparations on Treponema pallidum and Neisseria gonorrhoeae. British Journal of Venereal Disease 1972; 48:57-64.
14. Cates W, Stewart F, Trussell J. Commentary: The quest for women's prophylactic methods - hopes vs science. Am J Public Health 1992; 82:1479-1482.
15. Hatcher RA, Trussell J, Stewart F, et al. Contraceptive Technology. 16th ed (revised). New York: Irvington Publishers, 1994:183-185.
16. Centers for Disease Control and Prevention. 1993 Sexually Transmitted Diseases Treatment Guidelines. MMWR Morb Mortal Wkly Rep 1993; 42(RR-14).
17. d'Oro LC, Parazzini F, Naldi L, La Vecchia C. Barrier methods of contraception, spermicides, and sexually transmitted diseases: A review. Genitourin Med 1994; 70:410-417.
18. Bird K. The use of spermicide containing nonoxynol-9 in the prevention of HIV infection. AIDS 1991; 5:791-796.
19. McGregor JA, Hammill HA. Contraception and sexually transmitted diseases: Interactions and opportunities. Am J Obstet Gynecol 1993; 168:2033-2041.
20. McGroarty JA, Reid G, Bruce AW. The influence of nonoxynol-9 containing spermicides on urogenital infection. J Urol 1994; 152:831-833.
21. Stone K, Peterson H. Spermicides, HIV, and the vaginal sponge. JAMA 1992; 268:521-523.
22. Stein Z. Editorial: The double bind in science policy and the protection of women from HIV infection. Am J Public Health 1992; 82:1471-1472.
23. Potts M. The urgent need for a vaginal microbicide in the prevention of HIV transmission. Am J Public Health 1994; 84:890-891.
24. New York State Department of Health AIDS Institute. Women and HIV prevention: Methods of personal protection. Focus on AIDS in New York State: A Newsletter of the New York State Department of Health AIDS Institute, July 1992; 6-7.
25. Rendon AL, Covarrubias J, McCarney KE, Marion-Landais G, Luna del Villar J. A controlled, comparative study of phenylmercuric acetate, nonoxynol-9 and placebo vaginal suppositories as prophylactic agents against gonorrhea. Curr Ther Res 1980; 27:780-783.
26. Kreiss J, Ngugi E, Holmes K, et al. Efficacy of nonoxynol-9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 1992; 268:477-482.
27. Petitti DB. Meta-Analysis, Decision Analysis and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine. New York: Oxford University Press, 1994:90-114.
28. Niruthisard S, Roddy RE, Chutivongse S. Use of nonoxynol-9 and reduction in rate of gonococcal and chlamydial cervical infections. Lancet 1992; 339:1371-1375.
29. Louv WC, Austin H, Alexander J, Stagno S, Cheeks J. A clinical trial of nonoxynol-9 for preventing gonococcal and chlamydial infections. J Infect Dis 1988; 158:518-523.
30. Rosenberg M, Rojanapithayakom W, Feldblum PJ, Higgins JE. Effect of the contraceptive sponge on chlamydial infection, gonorrhea, and candidiasis. JAMA 1987; 257:2308-2312.
31. Cutler JC, Singh B, Uri C, et al. Vaginal contraceptives as prophylaxis against gonorrhea and other sexually transmissible diseases. Advanced Planned Parenthood 1977; 12:45-56.
32. Zeking L, Feldblum PJ, Oliver RM, Kaptue L. Barrier contraceptive use and HIV infection among high-risk women in Cameroon. AIDS 1993; 7:725-731.
33. Weir SS, Feldblum PJ, Zeking L, Roddy RE. The use of nonoxynol-9 for protection against cervical gonorrhea. Am J Public Health 1994; 84:910-914.
34. Rosenberg M, Davidson AJ, Chen JH, Judson FN, Douglas JM. Barrier contraceptives and sexually transmitted diseases in women: A comparison of female-dependent methods and condoms. Am J Public Health 1992; 82:669-674.
35. Quinn RW, O'Reilly KR. Contraceptive practices of women attending the sexually transmitted disease clinic in Nashville, Tennessee. Sex Transm Dis 1985; 12:99-102.
36. Austin H, Louv WC, Alexander J. A case-control study of spermicides and gonorrhea. JAMA 1984; 251:2822-2824.
37. Jick H, Hannan M, Stergachis A, Heidrich F, Perera D, Rothman K. Vaginal spermicides and gonorrhea. JAMA 1982; 248:1619-1621.
38. Cole CH, Lacher TG, Bailey JC, Fairclough DL. Vaginal chemoprophylaxis in the reduction of reinfection in women with gonorrhea. British Journal of Venereal Disease 1980; 56:314-318.
39. Berger GS, Keith L, Moss W. Prevalence of gonorrhoea among women using various methods of contraception. British Journal of Venereal Disease 1975; 51:307-309.
40. Bradbeer CS, Thin RN, Tan T, Thirumoorthy T. Prophylaxis against infection in Sinagporean prostitutes. Genitourin Med 1988; 64:52-53.
41. Park BJ, Strergachis A, Scholes D, Heirdrich FE, Holmes KK, Stamm WE. Contraceptive methods and the risk of Chlamydia trachomatis Infection in young women. Am J Epidemiol 1995; 142:771-778.
42. Barbone F, Austin H, Louv WC, Alexander WJ. A follow-up study of methods of contraception, sexual activity, and rates of trichomoniasis, candidiasis, and bacterial vaginosis. Am J Obstet Gynecol 1990; 163:510-514.
43. Kelaghan J, Rubin G, Ory H, Layde P. Barrier-method contraceptives and pelvic inflammatory disease. JAMA 1982; 248:184-187.
44. Marion-Landais G. El uso di un ovulo anticonceptivo como quimio-profilactico de las enfermedades sexualmente transmisibles. Salud Publica Mex 1981; 23:345-352.
45. Roddy RE, Cordero M, Cordero C, Fortney J. A dosing study of nonoxynol-9 and genital irritation. Int J STD AIDS 1993; 4:165-170.
46. Moench T, Whaley K, Mandrell T, Bishop B, Witt C, Cone R. The cat/feline immunodeficiency viras model for transmucosal transmission of AIDS: Nonoxynol-9 contraceptive jelly blocks transmission by an infected cell inoculum. AIDS 1993; 7:797-802.
47. Miller CJ, Alexander NJ, Gettie A, Hendrickx AG, Marx PA. The effect of contraceptives containing nonoxynol-9 on the genital transmission of simian immunodeficiency virus in rhesus macaques. Fertil Steril 1992; 57:1126-1128.
48. Lee TY, Utidjian HMD, Singh B, Carpenter U, Cutler JC. Potential impact of chemical prophylaxis on the incidence of gonorrhea. British Journal of Venereal Disease 1972; 48:376-380.
49. Feldblum PJ, Weir SS. The protective effect of nonoxynol-9 against HIV infection [letter]. Am J Public Health 1994; 84:1032-1033.
50. Hill AB. The environment and disease: Association or causation? Proc R Soc Med 1965; 58:295-300.
51. Family Health International. FHI Study Examines N-9 Effect on STDs. Available from: URL:http://www.fhi.org/general/newsrel.html April, 1997:2-4.
52. Shapiro S. Meta-analysis/schmeta-analysis. Am J Epidemiol 1994; 140:771-778.
53. L'Abbe KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med 1987; 107:224-233.
54. Petitti DB. Of babies and bathwater. Am J Epidemiol 1994; 140:779-782.
55. Greenland S. Can meta-analysis be salvaged? Am J Epidemiol 1994; 140:783-787.
56. Weir SS, Roddy RE, Zeking L, Feldblum PJ. Nonoxynol-9 use, genital ulcers, and HIV infection in a cohort of sex workers. Genitourin Med 1995; 71:78-81.
57. Wasserheit JN. Epidemiologic synergy: Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 1992; 19:61-77.
58. Grosskurth H, Mosha F, Todd J, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: Randomised controlled trial. Lancet 1995;346: 530-536.
59. Steiner MJ, Glover LH, Bou-Saada I, Piedrahita C. Increasing barrier method use among oral contraceptive users at risk of STDs: What approach is best? Sex Transm Dis 1998;25:139-143.
60. Farr G, Castro LAA, Disantostefano R, Claassen E, Olguin F. Use of spermicide and impact of prophylactic condom use among sex workers in Santa Fe de Bogota, Columbia. Sex Transm Dis 1996; 23:206-212.